NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Price Target & More

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

Five Prime Therapeutics Inc (NASDAQ:FPRX) released its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.08. The biotechnology company had revenue of $32.49 million for the quarter, compared to the consensus estimate of $37.50 million. Five Prime Therapeutics had a negative net margin of 221.74% and a negative return on equity of 44.36%. View Five Prime Therapeutics' Earnings History.

8 equities research analysts have issued 1-year target prices for Five Prime Therapeutics' shares. Their forecasts range from $17.00 to $60.00. On average, they expect Five Prime Therapeutics' share price to reach $34.7143 in the next twelve months. This suggests a possible upside of 99.4% from the stock's current price. View Analyst Ratings for Five Prime Therapeutics.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Five Prime Therapeutics include Clovis Oncology (CLVS), Spectrum Pharmaceuticals (SPPI), Endo International (ENDP), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), TESARO (TSRO), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Myokardia (MYOK), Puma Biotechnology (PBYI), Prestige Brands (PBH) and Phibro Animal Health (PAHC).

Media coverage about FPRX stock has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Five Prime Therapeutics earned a daily sentiment score of 0.11 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 44.72 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Five Prime Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Fox Run Management L.L.C. (0.07%). Company insiders that own Five Prime Therapeutics stock include Francis Willard Sarena, Lewis T Williams, Peder Jensen and William R Ringo. View Institutional Ownership Trends for Five Prime Therapeutics.

FPRX stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. View Insider Buying and Selling for Five Prime Therapeutics.

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FPRX stock can currently be purchased for approximately $17.41.

Five Prime Therapeutics has a market capitalization of $607.71 million and generates $39.51 million in revenue each year. The biotechnology company earns $-150,220,000.00 in net income (profit) each year or ($5.38) on an earnings per share basis. Five Prime Therapeutics employs 216 workers across the globe.

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600.